Lyell Immunopharma
LYEL
62 hedge funds and large institutions have $1.22B invested in Lyell Immunopharma in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 18 closing their positions.
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
19% more funds holding
Funds holding: 52 → 62 (+10)
0.08% more ownership
Funds ownership: 1.64% → 1.72% (+0.08%)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
6% less capital invested
Capital invested by funds: $1.29B → $1.22B (-$72.7M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| 1 |
BlackRock
New York
|
+$17.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.4M |
| 3 |
HH
HSG Holding
Na,
Hong Kong
|
+$9.13M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.94M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$6.84M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$16.6M |
| 2 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$8.85M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.4M |
| 4 |
Goldman Sachs
New York
|
-$3.28M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MS
76
Maven Securities
St Helier,
Jersey
| – | -$197K | -610 | Closed |
|
77
Tudor Investment Corp
Stamford,
Connecticut
| – | -$194K | -598 | Closed |
|
|
RCMU
78
Rokos Capital Management (UK)
London,
United Kingdom
| – | -$81K | -250 | Closed |
|
|
KAM
79
Kirkoswald Asset Management
New York
| – | -$16K | -50 | Closed |
|
|
WCMNY
80
Westchester Capital Management (New York)
Valhalla,
New York
| – | -$8K | -25 | Closed |
|
LYEL Hedge Fund Activity: Q3 2021 in Review
62 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q3 2021, worth a combined $1.22B — down 5.6% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new LYEL positions and 18 closed out — a net gain of 10 holders — while 11 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $17.7M. The largest seller was Morgan Stanley, cutting an estimated $16.6M.
- 62 institutional investors held Lyell Immunopharma (LYEL) as of Q3 2021, up from 52 in Q2 2021.
- Funds reported $1.22B of Lyell Immunopharma stock for Q3 2021, down 5.6% quarter-over-quarter.
- 28 funds opened new Lyell Immunopharma positions in Q3 2021 and 18 closed out, a net change of +10 holders.
- The largest Lyell Immunopharma buyer in Q3 2021 was BlackRock, an estimated $17.7M added.
- The largest Lyell Immunopharma seller in Q3 2021 was Morgan Stanley, an estimated $16.6M sold.
Based on aggregated 13F filings for Q3 2021.